ROS1阳性-话题@MedSci

#ROS1阳性#

13篇内容 | 739人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1738263, encodeId=c3d01e3826343, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=Target Oncol:真实世界探索Crizotinib（克唑替尼）治疗ROS1阳性晚期非小细胞肺癌（NSCLC）患者的疗效, objectType=article, longId=295679, objectId=7f802956e901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f802956e901, replyNumber=0, likeNumber=35, createdTime=2022-03-02, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f802956e901, moduleTitle=Target Oncol:真实世界探索Crizotinib（克唑替尼）治疗ROS1阳性晚期非小细胞肺癌（NSCLC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f802956e901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738262, encodeId=f41c1e38262a6, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=Repotrectinib治疗ROS1阳性非小细胞肺癌，ORR高达93％, objectType=article, longId=206520, objectId=2862206520fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2862206520fd, replyNumber=0, likeNumber=41, createdTime=2021-03-15, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2862206520fd, moduleTitle=Repotrectinib治疗ROS1阳性非小细胞肺癌，ORR高达93％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2862206520fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738261, encodeId=b3471e38261cc, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者, objectType=article, longId=195930, objectId=68ef19593022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68ef19593022, replyNumber=0, likeNumber=30, createdTime=2020-08-05, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68ef19593022, moduleTitle=NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68ef19593022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738260, encodeId=60a91e3826082, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=精准医疗的突破：FoundationOne CDx癌症基因组谱可用于Rozlytrek治疗ROS1阳性肺癌的伴随诊断, objectType=article, longId=185334, objectId=f8d0185334ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8d0185334ad, replyNumber=0, likeNumber=48, createdTime=2020-02-27, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8d0185334ad, moduleTitle=精准医疗的突破：FoundationOne CDx癌症基因组谱可用于Rozlytrek治疗ROS1阳性肺癌的伴随诊断, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8d0185334ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738259, encodeId=34a01e3825934, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=Lancet Oncol：劳拉替尼治疗ROS1阳性的晚期NSCLC, objectType=article, longId=182127, objectId=ae9218212e1b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae9218212e1b, replyNumber=0, likeNumber=43, createdTime=2020-05-20, rootId=0, userName=124987a0m77(暂无昵称), userId=83fc34405672, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae9218212e1b, moduleTitle=Lancet Oncol：劳拉替尼治疗ROS1阳性的晚期NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae9218212e1b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738258, encodeId=d0011e3825839, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, objectType=article, longId=177801, objectId=78401e780141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78401e780141, replyNumber=0, likeNumber=40, createdTime=2019-12-05, rootId=0, userName=124987a0m77(暂无昵称), userId=83fc34405672, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78401e780141, moduleTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78401e780141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738256, encodeId=4d501e382560e, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=ROS1阳性非小细胞肺癌诊断病理专家共识, objectType=article, longId=136615, objectId=e43613661584, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e43613661584, replyNumber=0, likeNumber=28, createdTime=2018-10-19, rootId=0, userName=124987a0m77(暂无昵称), userId=83fc34405672, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e43613661584, moduleTitle=ROS1阳性非小细胞肺癌诊断病理专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e43613661584)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738257, encodeId=3e881e3825721, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南, objectType=article, longId=138096, objectId=5134138096d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5134138096d4, replyNumber=0, likeNumber=29, createdTime=2019-04-08, rootId=0, userName=124987a0m77(暂无昵称), userId=83fc34405672, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5134138096d4, moduleTitle=中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5134138096d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738255, encodeId=0f9b1e3825530, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=克唑替尼治疗有脑转移的进展期ROS1阳性NSCLC患者的临床疗效结果公布, objectType=article, longId=116746, objectId=50e2116e46bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50e2116e46bc, replyNumber=0, likeNumber=59, createdTime=2018-03-07, rootId=0, userName=124987a0m77(暂无昵称), userId=83fc34405672, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50e2116e46bc, moduleTitle=克唑替尼治疗有脑转移的进展期ROS1阳性NSCLC患者的临床疗效结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50e2116e46bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738253, encodeId=9ca71e382534f, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=KIT突变致ROS1阳性肺癌对克唑替尼耐药, objectType=article, longId=66750, objectId=265c66e50ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=265c66e50ea, replyNumber=0, likeNumber=57, createdTime=2016-08-18, rootId=0, userName=124987a0m77(暂无昵称), userId=83fc34405672, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=265c66e50ea, moduleTitle=KIT突变致ROS1阳性肺癌对克唑替尼耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=265c66e50ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738254, encodeId=81711e382544c, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=精准医疗典范：欧盟批准辉瑞靶向抗癌药Xalkori治疗ROS1阳性非小细胞肺癌（NSCLC）, objectType=article, longId=76572, objectId=8bfbe657216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8bfbe657216, replyNumber=0, likeNumber=39, createdTime=2017-02-07, rootId=0, userName=124987a0m77(暂无昵称), userId=83fc34405672, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8bfbe657216, moduleTitle=精准医疗典范：欧盟批准辉瑞靶向抗癌药Xalkori治疗ROS1阳性非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8bfbe657216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738252, encodeId=51fa1e3825299, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=生物标志物驱动精准医疗的又一典范：FDA批准辉瑞抗癌药Xalkori治疗ROS1阳性非小细胞肺癌, objectType=article, longId=64856, objectId=125f6485664, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=125f6485664, replyNumber=0, likeNumber=39, createdTime=2016-10-02, rootId=0, userName=124987a0m77(暂无昵称), userId=83fc34405672, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=125f6485664, moduleTitle=生物标志物驱动精准医疗的又一典范：FDA批准辉瑞抗癌药Xalkori治疗ROS1阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=125f6485664)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738251, encodeId=025d1e3825198, content=<a href='/topic/show?id=9b3e156346e' target=_blank style='color:#2F92EE;'>#ROS1阳性#</a>, objectTitle=ESMO 2014：克唑替尼可有效抑制ROS1阳性非小细胞肺癌的进展, objectType=article, longId=41397, objectId=a5934139eb6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5934139eb6, replyNumber=0, likeNumber=39, createdTime=2015-08-07, rootId=0, userName=124987a0m77(暂无昵称), userId=83fc34405672, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5934139eb6, moduleTitle=ESMO 2014：克唑替尼可有效抑制ROS1阳性非小细胞肺癌的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5934139eb6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ROS1阳性

2020-05-29

一叶知秋 (审核中...)

前往app查看评论内容

#ROS1阳性#

Target Oncol:真实世界探索Crizotinib（克唑替尼）治疗ROS1阳性晚期非小细胞肺癌（NSCLC）患者的疗效

2022-03-02

一叶知秋 (审核中...)

前往app查看评论内容

#ROS1阳性#

Repotrectinib治疗ROS1阳性非小细胞肺癌，ORR高达93％

2021-03-15

一叶知秋 (审核中...)

前往app查看评论内容

#ROS1阳性#

NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者

2020-08-05

一叶知秋 (审核中...)

前往app查看评论内容

#ROS1阳性#

精准医疗的突破：FoundationOne CDx癌症基因组谱可用于Rozlytrek治疗ROS1阳性肺癌的伴随诊断

2020-02-27

124987a0m77(暂无昵称) (审核中...)

前往app查看评论内容

#ROS1阳性#

Lancet Oncol：劳拉替尼治疗ROS1阳性的晚期NSCLC

2020-05-20

124987a0m77(暂无昵称) (审核中...)

前往app查看评论内容

#ROS1阳性#

罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC

2019-12-05

124987a0m77(暂无昵称) (审核中...)

前往app查看评论内容

#ROS1阳性#

ROS1阳性非小细胞肺癌诊断病理专家共识

2018-10-19

124987a0m77(暂无昵称) (审核中...)

前往app查看评论内容

#ROS1阳性#

中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南

2019-04-08

124987a0m77(暂无昵称) (审核中...)

前往app查看评论内容

#ROS1阳性#

克唑替尼治疗有脑转移的进展期ROS1阳性NSCLC患者的临床疗效结果公布

2018-03-07

124987a0m77(暂无昵称) (审核中...)

前往app查看评论内容

#ROS1阳性#

KIT突变致ROS1阳性肺癌对克唑替尼耐药

2016-08-18

124987a0m77(暂无昵称) (审核中...)

前往app查看评论内容

#ROS1阳性#

精准医疗典范：欧盟批准辉瑞靶向抗癌药Xalkori治疗ROS1阳性非小细胞肺癌（NSCLC）

2017-02-07

124987a0m77(暂无昵称) (审核中...)

前往app查看评论内容

#ROS1阳性#

生物标志物驱动精准医疗的又一典范：FDA批准辉瑞抗癌药Xalkori治疗ROS1阳性非小细胞肺癌

2016-10-02

124987a0m77(暂无昵称) (审核中...)

前往app查看评论内容

#ROS1阳性#

ESMO 2014：克唑替尼可有效抑制ROS1阳性非小细胞肺癌的进展

2015-08-07

科室
- - 订阅+
  - 更多科室
工具
服务